Based on their mechanism of action and data from animal studies, IMFINZI and IMJUDO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and IM...
Other chemotherapeutic agents administered in combination include ICE (ifosfamide, carboplatin, etoposide) and bendamustine hydrochloride [139]. Programmed cell death ligand (PD-1) is upregulated in most EBV-related cancer; in normal cells, it works as a checkpoint for regulating the activation of ...
The combination of olaparib with CPI therapy have led to results consistent with the discussed benefit of olaparib monotherapy for patients with mCRPC and DDR alterations. In one phase II clinical trial, olaparib was explored in combination with an anti-PD-L1 antibody, durvalumab. Of the 17 patie...
Patients are currently being recruited for the first trials evaluating the efficacy of the anti-programmed death ligand-1 (PD-L1) agent durvalumab, as a monotherapy or in combination with pomalidomide with or without dexamethasone (NCT02616640). A phase 1/2 study of the new anti-PD-1 agent ...
When appropriate, some drugs that are usually administered via a minibag infusion can be administered as an IV bolus (push) or, if an oral equivalent agent is available, administered by mouth. Because of the potential for inadvertent intrathecal administration, anticancer drugs are rar...
However, the reported survival advantage has been modest in subsequent trials, and many combinations with different drugs including checkpoint inhibitors (e.g., durvalumab) or targeted therapies (e.g., glasdegib, histone deacetylase inhibitors) have been tried without incremental improvements of outcomes...
What remains controversial, however, is the role of HDCT as first-line salvage therapy in relapsed patients with highly favorable risk profiles. In order to avoid overtreatment, HDCT should only be administered at specialist centres with the necessary expertise....
Current clinical practice in advanced NSCLC is largely based on results from the phase 3 PACIFIC trial [95], which demonstrated the benefit of consolidation therapy with the PD-L1 inhibitor Durvalumab in patients who did not have disease progression after two or more cycles of chemo-radiotherapy....
Cancer, also known as malignant tumour or neoplasm, is a leading cause of death worldwide. One distinct feature from normal cells is that cancerous cells often overexpress protein on the cell membrane—for instance, the overexpression of human epidermal growth factor receptor 2. The expression of...